BNP Paribas Reaffirms “Outperform” Rating for Shire (SHP)

BNP Paribas reiterated their outperform rating on shares of Shire (LON:SHP) in a report issued on Tuesday. They currently have a GBX 4,700 ($63.74) price target on the biopharmaceutical company’s stock.

SHP has been the subject of several other research reports. JPMorgan Chase & Co. restated an overweight rating and issued a GBX 5,300 ($71.87) price target on shares of Shire in a report on Monday, October 30th. Shore Capital reiterated a buy rating on shares of Shire in a report on Monday, January 15th. Liberum Capital decreased their target price on Shire from GBX 4,400 ($59.67) to GBX 4,200 ($56.96) and set a hold rating for the company in a report on Tuesday, October 24th. Barclays reiterated an equal weight rating and set a GBX 4,000 ($54.24) target price on shares of Shire in a report on Monday, October 30th. Finally, Deutsche Bank reiterated a buy rating on shares of Shire in a report on Monday, December 11th. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of GBX 5,082.35 ($68.92).

Shares of Shire (LON SHP) opened at GBX 3,461 ($46.94) on Tuesday. The company has a market capitalization of $31,340.00 and a PE ratio of 2,725.20. Shire has a fifty-two week low of GBX 3,403.50 ($46.16) and a fifty-two week high of GBX 5,067 ($68.71).

In related news, insider Dominic Blakemore purchased 165 shares of the firm’s stock in a transaction on Tuesday, December 19th. The stock was purchased at an average price of GBX 3,790 ($51.40) per share, for a total transaction of £6,253.50 ($8,480.47).

COPYRIGHT VIOLATION NOTICE: “BNP Paribas Reaffirms “Outperform” Rating for Shire (SHP)” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://sportsperspectives.com/2018/01/20/bnp-paribas-reaffirms-outperform-rating-for-shire-shp.html.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (LON:SHP)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply